Structured evidence table for Saffron Depression Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Saffron Depression Meta-Analysis | A Swiss study found that 10% of participants experienced PMS, whereas 3% experienced PMDD. | 1 | Mohammadi Mohammad Mehdi (2026) | Effect of saffron on premenstrual syndrome and dysmenorrhea: a systematic review and meta-analysis |
| Saffron Depression Meta-Analysis | These challenges include legal issues, suicidal ideation, reduced work productivity, social isolation, parenting difficulties, increased absenteeism, disruptions of personal and social relationships, and frequent hospital visits. | 1 | Mohammadi Mohammad Mehdi (2026) | Effect of saffron on premenstrual syndrome and dysmenorrhea: a systematic review and meta-analysis |
| Saffron Depression Meta-Analysis | PMS and dysmenorrhea can also contribute to increased susceptibility to accidents, drug addiction, financial losses, and diminished achievements []. | 1 | Mohammadi Mohammad Mehdi (2026) | Effect of saffron on premenstrual syndrome and dysmenorrhea: a systematic review and meta-analysis |
| Saffron Depression Meta-Analysis | 1 2 2 3 1 4 5 6 Premenstrual syndrome (PMS) refers to a range of psychological, emotional and behavioral symptoms that occur prior to menstruation []. | 1 | Mohammadi Mohammad Mehdi (2026) | Effect of saffron on premenstrual syndrome and dysmenorrhea: a systematic review and meta-analysis |
| Saffron Depression Meta-Analysis | This literature review synthesises evidence from randomised controlled trials, meta-analyses, safety data, dosing patterns, proposed mechanisms, and guideline positioning regarding saffron in depression, with a focus on adult major depressive disorder and related depressive symptomatology. | 4 | Dimech L (2026) | The Role of Saffron in the Treatment of Depression: A Literature Review. |
| Saffron Depression Meta-Analysis | Across placebo-controlled trials in mild-to-moderate depression, saffron, most commonly administered at 30 mg per day for approximately six weeks, has been associated with clinically meaningful reductions in depressive symptom severity, typically measured using the Hamilton Depression Rating Scale (HAM-D). | 4 | Dimech L (2026) | The Role of Saffron in the Treatment of Depression: A Literature Review. |
| Saffron Depression Meta-Analysis | Meta-analytic evidence generally indicates superiority over placebo and similar efficacy to selective serotonin reuptake inhibitors (SSRIs), with an overall favourable short-term tolerability profile; however, confidence is constrained by small sample sizes, restricted settings, variable product standardisation (including stigma versus petal preparations), and risk of bias/publication bias. | 4 | Dimech L (2026) | The Role of Saffron in the Treatment of Depression: A Literature Review. |
| Saffron Depression Meta-Analysis | Saffron ( Crocus sativus L.) has attracted increasing interest as a nutraceutical option for depressive disorders, particularly for patients who experience incomplete response or poor tolerability with conventional treatments. | 4 | Dimech L (2026) | The Role of Saffron in the Treatment of Depression: A Literature Review. |
Source documents